Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Clinical translation of carfilzomib trial data for MM treatment

Greg Friberg • 9 Dec 2017
ASH 2017
Multiple Myeloma Carfilzomib
ASPIRE ENDEAVOUR

The proteasome inhibitor carfilzomib has been investigated for the treatment of relapsed/refractory multiple myeloma (MM) in two Phase III clinical trials, ASPIRE (NCT01080391) and ENDEAVOUR (NCT01080391), with promising results. In this interview, Greg Friberg, MD, of Amgen Inc., Thousand Oaks, CA, discuses subanalyses of the robustness of the study data. Dr Friberg highlights how this data will help clinicians to determine the best treatment combinations for their patients. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Greg Friberg

1:04
Results of the ASPIRE trial for MM: the addition of carfilzomib
Greg Friberg • 9 Dec 2017

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals